Automated Control of End-tidal Volatile Anesthetic Concentration

Automated Control of End-tidal Volatile Anesthetic Concentration Using the MIRUS System: A Comparison of Isoflurane, Sevoflurane and Desflurane in Anesthesia.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02342509

Acronym

MIRCONTROL

Enrollment

Registered

2015-01-21

Start date

2014-09-30

Completion date

2014-12-31

Last updated

2015-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delayed Recovery From Anesthesia

Keywords

et Control, inhalational sedation, conserve volatile anesthetics

Brief summary

The new MIRUS system as well as the established AnaConDa system uses a reflector to conserve volatile anaesthetics (VA). Both systems act with commercially available ICU ventilators. In contrast to AnaConDa the MIRUS includes an automated control of end-tidal VA concentrations. In this study the investigators compared feasibility, costs and recovery times after anaesthesia with isoflurane (ISO), sevoflurane (SEVO) or desflurane (DES) in ventilated and spontaneously breathing patients.

Detailed description

The study was approved by the appropriate Institutional Review Board. After written informed consent 63 ASA I-III patients undergoing elective hip or knee replacement surgery under general anesthesia were included. Patients were randomly organized into 3 groups (20-22 each). Anesthesia was induced with intravenous anaesthetics. After tracheal intubation MIRUS automatically adjusted the end-tidal VA concentration to 1.0 MAC. Patients were ventilated with the Puritan Bennett 840 ICU ventilator. After 1 h of anaesthesia with 1.0 MAC the ventilator mode was switched from SIMV V+ (totally controlled ventilation, passive patient, with a tidal volume of 8 ml/IBW) to proportional assist ventilation (PAV) with 50% support (active patient). At the end of surgery the MIRUS system was stopped (MAC set to 0.0) and recovery times were measured.

Interventions

DRUGDesflurane

Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)

DRUGSevoflurane

Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)

DRUGIsoflurane

Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signing of the informed consent document (patient or relatives). * Patient age 18 years or older. * ASA I-III

Exclusion criteria

* ASA IV patients * Epidural or spinal analgesia * Allergy or known hypersensitivity to any of the study drugs * Patients with known or suspected genetic susceptibility to malignant hyperthermia * Previous participation in this trial * Participation in another clinical trial within 4 weeks prior to selection. * Pregnant women

Design outcomes

Primary

Measure	Time frame
volatile anaesthetics (VA) consumption	duration of anesthesia: max. 3 h

Secondary

Measure	Time frame
recovery times	duration post anesthesia care: max. 8 h after anesthesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026